Physician profile
Sharon Stecher
NPI 1518142116
$7,720.91
in general payments reported to CMS, 2019-2025
16 companies · $2,205 in 2025
The $2,205 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,582 · 2022: $941 · 2023: $1,544 · 2024: $1,448 · 2025: $2,205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,149 · Education: $48.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,148.69 |
| Education | $48.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,691.24 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,150.00 | 2021-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $1,002.39 | 2024-2025 | Fanapt |
| Janssen Pharmaceuticals, INC | $855.72 | 2021-2024 | Invega Sustenna, Invega Trinza |
| E.R. Squibb & Sons, L.L.C. | $522.20 | 2024-2025 | Cobenfy |
| Abbvie INC. | $444.62 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $444.37 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $406.06 | 2021-2025 | Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $363.35 | 2021-2024 | Ongentys, Ingrezza |
| Validus Pharmaceuticals LLC | $260.46 | 2021-2023 | Equetro |
| Axsome Therapeutics, INC. | $233.61 | 2023-2025 | Auvelity |
| Avanir Pharmaceuticals, INC. | $129.09 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $99.54 | 2023 | |
| Coloplast Corp | $74.86 | 2023 | Titan |
| Lundbeck LLC | $27.06 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $16.34 | 2024 | Brixadi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Stecher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.